International Symposium

4th International Definiens Symposium - Boston 2013


EVENT DATE: May 13 - May 15, 2013
EVENT HOST: Definiens
EVENT LOCATION: Boston, Massachusetts
EVENT WEB LINK: Event URL Coming Soon
EVENT AGENDA: Download

The Symposium opened with two days of plenary lectures at the Joseph B Martin Conference Center on the Harvard Medical School Campus. Topics focused on advancing drug development and the future of digital pathology and image analysis.


Presentations

Keynote Lecture: Cellular Image Analysis: Where have we been and where are we going?
Dr Kenneth J Bloom, CMO Clarient, Aliso Viejo, CA

Millennium Pharmaceuticals: A Business Case Study for Utilizing the Definiens Platform in Multiple Image Analysis Workflows for IHC-based Biomarkers in Preclinical and Clinical Models
Dr Doug Bowman, Senior Scientist II Millennium Pharmaceuticals, Cambridge, MA

Computational Pathology for Cancer Diagnostics and Translational Research
Dr Andrew Beck, Assistant Professor, Department of Pathology Harvard Medical School, Boston, MA

Assessing Ovarian Toxicity with Digital Pathology
Dr Jens Brodbeck, Scientist, Department for Safety Assessment Genentech, South San Francisco, CA

Definiens in Colorectal Cancer Prognosis: Standardised Quantification of Histopathological Features for Patient Stratification
Peter Caie, Quantitative and Systems Pathology, Division of Pathology, College of Medicine and Veterinary Medicine, University of Edinburgh, UK

Digital Pathology: The Investor’s Perspective
Dr Janke Dittmer, Partner Gilde Healthcare Partners, Utrecht, NL

Quantitative Analysis of Hypoxia with Correlation of PET/CT images with Histology for Patientderived Colon Cancer Mouse Xenografts
Trevor Do, STTARR Innovation Program, Princess Margaret Hospital University Health Network, Toronto, CAN

The Immunoscore: A Novel Approach for the Classification of Cancer in the Era of Immunotherapies
Prof Dr Jérôme Galon, Research Director, Laboratory of Integrative Cancer Immunology INSERM, Cordeliers Research Center, Paris, France

Accelerating Tissue-Based Research with the New Release of the Definiens Product Suite
Kai Hartmann, Director, Product Marketing Life Sciences Definiens, Munich, Germany

Primary Cilia are Lost Early in Prostate Cancer Progression
Nadia B. Hassounah, Department of Cell Biology & Anatomy The University of Arizona Cancer Center, Tucson, AZ

The Medical Value of Digital Pathology
Ralf Huss, Chief Medical Officer Definiens AG, Munich

Quantification of Epidermal Growth Factor Receptor Immunohistochemistry in Advanced Colorectal Cancer
Ryan Hutchinson, Northern Ireland Molecular Pathology Centre for Cancer Research and Cell Biology, Queen’s University Belfast, UK

Single-Cell RNA Quantification in situ via RNAscope SpotStudio
Dr Xiao-Jun Ma, CSO Advanced Cell Diagnostics, Hayward, CA

Beyond the “Nuclear Option”: Sophisticated Digital Analysis Adds Value to Researchers’ Work and to a Core Lab’s Worth
Dr Clara E. Magyar, Manager, Translational Pathology Core Laboratory, Department of Pathology UCLA School of Medicine, Los Angeles, CA

Quantitative Analysis of the Adaptive Immune Response in the Bone Marrow Survival Niche
Dr Franziska Mech

Application of Advanced Image Analysis to 3D and 4D Quantitative Imaging of Proteolytic Activity in Live Cells
Dr Kamiar Moin, Associate Professor of Pharmacology Wayne State University and Karmanos Cancer Institute, Detroit, MI

Fuzzy Logic Cell-Based Metrics Enhance High Content Screening Assay Robustness
Dr María Montoya

Automatic Segmentation of Pathological Features in Glioblastoma Multiforme
Chantal Murthy, Swedish Medical Center, Seattle, WA

Optimizing Efficiency of a Clinical Molecular Diagnostic Assay using an Integrated, Fully- Automated Image Analysis Workflow
Dr Tom Nifong, Vice President of Clinical Operations Metamark Genetics, Cambridge, MA

Quantification of Glomerular Injury using Definiens Tissue Studio
Alan Opsahl, Senior Scientist, Investigative Pathology Laboratory, Drug Safety Research and Development (DSRD) Pfizer, Groton, CT

Therapy-Relevant Stratification of Breast Cancer based on in situ Immunofluorescence Protein Quantification
Dr Hallgeir Rui, Professor Cancer Biology Kimmel Cancer Center, Philadelphia, PA

Analysis of Drug Response Read-Outs in Xenograft Tissue using Definiens Tissue Studio
Dr Lorcan Sherry, CSO OracleBio, Glasgow, UK

Integrating Definiens in the Molecular Pathology Workflow
Dr Thomas T. Tibbitts, Research Director Infinity Pharmaceuticals, Cambridge, MA

Cognition Network Technology as an Enabling Technology for Zebrafish Drug Discovery
Dr Andreas Vogt, Group Leader, Small Organism Discovery, UPDDI & Associate Professor, Comp Sys Bio University of Pittsburgh Drug Discovery Institute, Pittsburgh, PA

Definiens Integration into an Imaging Management System
Dr Teodor Wagner

Modification of Staining Techniques to Make Rule Set Development and Image Analysis More Efficient
James Watson HT ASCP, Facilities Manager of Histology GNF Genomics Institute of the Novartis Research Foundation, San Diego, CA